QRX 003
Alternative Names: QRX-003Latest Information Update: 27 Apr 2024
At a glance
- Originator Quoin Pharmaceuticals
- Class Anti-inflammatories; Skin disorder therapies; Small molecules
- Mechanism of Action Serine protease inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II/III Netherton Syndrome
- Preclinical Palmoplantar keratoderma; Skin disorders